Phase I/II study of docetaxel and S-1 in previously treated patients with advanced non-small cell lung cancer
Not Applicable
- Conditions
- previously treated patients with advanced non-small cell lung cancer
- Registration Number
- JPRN-UMIN000038464
- Lead Sponsor
- Clinical Research Support Center Kyushu
- Brief Summary
The median period of follow-up was 8 months(range, 1~39 months). The response to treatment was as follows: complete response, 0; partial response, 3; stable disease, 24; PD, 5; and no effect, 7.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 39
Inclusion Criteria
Not provided
Exclusion Criteria
active infection, massive ascites or pleural effusion symptomatic brain metastasis uncontrollable diabetes mellitus severe comorbidity such as heart disease or renal disease, interstitial pneumonia, watery diarrhea, active concomitant malignancy pregnancy or lactation, or other medical problems severe enough to prevent compliance with the protocol Both of the following conditions were necessary an interval of at least 4 weeks after the end of final therapy and recovery from the previous treatment
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine a recommended dose, ORR
- Secondary Outcome Measures
Name Time Method